The State of Peptide Research in 2026
Peptide research has entered a golden era, with more clinical trials, published papers, and investigational compounds than at any point in history. This overview covers the major research frontiers and scientific developments shaping the field.
Metabolic Research Frontiers
The GLP-1 agonist class continues to expand with semaglutide, tirzepatide, and retatrutide pushing boundaries on what incretin-based compounds can achieve. The move from single to triple agonism represents a trend toward comprehensive pathway modulation.
Regenerative Medicine
Tissue repair peptides like BPC-157 and TB-500 continue to accumulate preclinical evidence for applications in tendon, ligament, GI, and neurological repair research.
Longevity & Anti-Aging
NAD+ restoration, mitochondrial peptides (MOTS-C), and GH optimization through secretagogues like ipamorelin represent distinct approaches to aging research, each targeting different hallmarks of aging.
Neuroscience
Nootropic peptides (Semax, Selank) and neuroprotective compounds (BPC-157, GHK-Cu) are expanding neuroscience research toolkits beyond traditional small-molecule pharmacology.
Future Directions
Key areas to watch: oral peptide delivery, peptide-antibody conjugates, AI-designed peptides, and multi-target compounds that address complex disease networks rather than single pathways.
For research purposes only. Catalog | COAs